<DOC>
	<DOCNO>NCT00721201</DOCNO>
	<brief_summary>The purpose study assess effect reduce activity endogenous glucocorticoid patient low-grade cortisol excess</brief_summary>
	<brief_title>Glucocorticoid Receptor Antagonism Subclinical Cushings</brief_title>
	<detailed_description />
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Patients eligible inclusion : male 18 , lack clinical feature classically associate Cushing 's syndrome ; evidence excess circulate cortisol Evidence local systemic malignancy ; overt Cushing 's syndrome ; severe uncontrolled diabetes mellitus hypertension ; pregnancy ; clinically significantly impaired cardiovascular function ( e.g . stage IV cardiac failure ) ; severe liver disease ( liver enzymes â‰¥ 3 x institutional upper limit normal range ) ; significantly impair renal function ( eGFR &lt; 30/min ) ; uncontrolled severe active infection ; treatment approve experimental steroidogenesis inhibitor , adrenolytic agent , within four week admission ; In woman , know endometrial cancer , history endometrial hyperplasia vaginal bleed unknown cause ; requirement inhale systemic glucocorticoid exist disease ; impaired mental capacity markedly abnormal psychiatric evaluation precludes informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>subclinical Cushing 's</keyword>
</DOC>